STOCK TITAN

IRIDEX Corp director increases stake with open-market share buys

Filing Impact
(Neutral)
Filing Sentiment
(Positive)
Form Type
4

Rhea-AI Filing Summary

IRIDEX Corporation (IRIX) director share purchases disclosed. A company director reported open-market purchases of common stock in two transactions. On 11/14/2025, the director bought 28,157 shares at a weighted average price of $0.9676 per share, in multiple trades between $0.9367 and $0.98. On 11/17/2025, the director bought 21,843 shares at a weighted average price of $0.9654 per share, in multiple trades between $0.95 and $0.98.

After these transactions, the director beneficially owns 250,674 shares directly. In addition, 69,300 shares are held indirectly by the director’s spouse, and 30,026 shares are held indirectly through trusts identified in the footnotes. The filing notes that detailed trade‑by‑trade pricing information is available upon request.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
MOORE WILLIAM M

(Last) (First) (Middle)
1212 TERRA BELLA AVENUE

(Street)
MOUNTAIN VIEW CA 94043

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
IRIDEX CORP [ IRIX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
11/14/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/14/2025 P 28,157 A $0.9676(1) 228,831 D
Common Stock 11/17/2025 P 21,843 A $0.9654(2) 250,674 D
Common Stock 69,300 I By Spouse
Common Stock 30,026 I See Footnote(3)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.9367 to $0.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price.
2. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.95 to $0.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price.
3. The shares are held by William M. Moore Trust, William M. Moore, Trustee Under Agreement Dated 08/16/2016 & Patricia A. Moore Trust, Patricia A. Moore, Trustee Under Agreement Dated 08/17/2016 Tenants in Common.
/s/ Nilo De Castro, Attorney-in-fact for William M. Moore 11/18/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did IRIDEX (IRIX) report in this Form 4?

The filing reports that a director of IRIDEX purchased common stock in the open market in two separate transactions on 11/14/2025 and 11/17/2025.

How many IRIDEX (IRIX) shares did the director purchase and at what prices?

The director bought 28,157 shares on 11/14/2025 at a weighted average price of $0.9676, and 21,843 shares on 11/17/2025 at a weighted average price of $0.9654.

How many IRIDEX (IRIX) shares does the director own after these transactions?

Following the reported trades, the director beneficially owns 250,674 shares directly, plus 69,300 shares held indirectly by a spouse and 30,026 shares held indirectly through specified trusts.

Were the IRIDEX (IRIX) director’s purchases made in multiple trades?

Yes. Each weighted average price reflects multiple transactions: 11/14/2025 trades ranged from $0.9367 to $0.98, and 11/17/2025 trades ranged from $0.95 to $0.98.

Does this IRIDEX (IRIX) Form 4 include any derivative securities?

No derivative securities are reported in the excerpted Table II; only common stock acquisitions are shown in Table I.

Who signed the IRIDEX (IRIX) Form 4 for the reporting person?

The Form 4 was signed by /s/ Nilo De Castro as attorney-in-fact for the reporting person, William M. Moore.

Iridex

NASDAQ:IRIX

IRIX Rankings

IRIX Latest News

IRIX Latest SEC Filings

IRIX Stock Data

23.72M
11.94M
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States
MOUNTAIN VIEW